XOMA to Announce First Quarter 2015 Financial Results and Host Conference Call on May 7

BERKELEY, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Thursday, May 7, 2015, at 4:30 p.m. Eastern time to discuss first quarter 2015 financial results and provide an update on gevokizumab's global clinical programs.

The webcast can be accessed via the Investors & Media section of XOMA's website at http://investors.xoma.com/events.cfm and will be available for replay until close of business on August 7, 2015. Telephone numbers for the live audiocast are 877-369-6589 (U.S./Canada) and 408-337-0122 (international).

About XOMA Corporation

XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates are the result of the Company's expertise in developing ground-breaking monoclonal antibodies, including allosteric modulating antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Servier through a global Phase 3 program for Behçet's disease uveitis and non-infectious uveitis. XOMA also has an ongoing Phase 3 study of gevokizumab in pyoderma gangrenosum. Additionally, XOMA's scientific research has produced the XMet platform, which consists of three classes of Selective Insulin Receptor Modulators (SIRMs) antibodies. XOMA 358, the lead antibody in the XMetD program, is an allosteric modulating monoclonal antibody that reduces the binding of insulin to its receptor, down-regulates insulin signaling and could have a major effect on the treatment of abnormal metabolic states. XOMA 358 recently completed Phase 1 testing. For more information, visit www.xoma.com.

CONTACT: XOMA Corporation

         Company and Investor Contact:
         Ashleigh Barreto
         510-204-7482
         [email protected]

         Juliane Snowden
         The Oratorium Group, LLC
         [email protected]

         Media contact:
         Ryan Flinn
         W2O Group
         415-946-1059
         [email protected]

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Universal Logistics Holdings, Inc. (ULH) Tops Q1 EPS by 136c
• USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c